• S&P 500: 1,342.64
  • Change: -0.69%
$0.60 0.00 (-0.33%)
2/10/2012 3:59 PM

Rexahn Pharmaceuticals (AMEX:RNN)

CAPS Rating: 2 out of 5

Current Price $0.60 Mkt Cap $56.95M
Open $0.59 P/E Ratio 0.00
Prev. Close $0.60 Div. (Yield) N/A (N/A)
Daily Range $0.57 - $0.62 Volume 47,511
52-Wk Range $0.34 - $1.83 Avg. Daily Vol. 0

News & Discussion Boards

Caps

This ticker is not currently Ratable.

All Players

55 Outperform
12 Underperform
 

All-Star Players

7 Outperform
6 Underperform
 

Wall Street

1 Outperform
0 Underperform
 

Top RNN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Louiethelooper (< 20)
Submitted April 20, 2010

Investors misunderstood Dr. Ahn's NYC announcement about Serdaxin results. The man used to work for the FDA and has been in scientific research all his life. He's no fool. He didn't travel all the way to NYC to try to hoodwink Wall Street. Serdaxin… More

1 Comment | Reply | Report this Post

zzlangerhans (99.27)
Submitted January 19, 2012

Stocks like Rexahn are pure fire, and I'd rather get burned in CAPS than in real life. That's what happened when I got greedy for score leaderships and tried to catch an upswing in Rexahn that never came. In November, the phase IIb trial of Serdaxin… More

Add Comment | Reply | Report this Post
RNN VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about RNN.

Recs

0
Member Avatar grhebert (< 20) Submitted: 1/22/2012 6:51:39 PM : Outperform Start Price: $0.53 RNN Score: +11.15

Future drug development

Report this Post Add Comment | Reply | Permalink

Recs

1
Member Avatar zzlangerhans (99.27) Submitted: 1/19/2012 12:02:55 AM : Underperform Start Price: $0.51 RNN Score: -13.89

Stocks like Rexahn are pure fire, and I'd rather get burned in CAPS than in real life. That's what happened when I got greedy for score leaderships and tried to catch an upswing in Rexahn that never came. In November, the phase IIb trial of Serdaxin in depression was a failure and my score got flushed from the toilet into the sewer.

Once there was no hope of recovery, I ended my losing pick and reassessed the situation. Rexahn has unceremoniously shelved development of their two clavulanic acid compounds, Serdaxin and Zoraxel, in favor of Akt-1 kinase inhibitor Archexin as well as some new cancer drugs in early development. The next significant catalyst will be data from the phase IIa trial of Archexin in pancreatic cancer, now pushed back to Q3 2012. I have very dim hopes for success in this trial and I don't expect Rexahn stock to perform well in the catalyst-free months ahead of the data release. Hopefully I'm back on the Rexahn horse to stay.

Report this Post Add Comment | Reply | Permalink

Recs

0
Member Avatar polaris420 (< 20) Submitted: 2/26/2011 3:46:10 PM : Outperform Start Price: $1.70 RNN Score: -65.98

The satisfaction of investing in a comany that has the patient first. Rexahn Pharmaceuticals has been developing their Serdaxin and other drugs with this honorable concept.I recommend, read for yourself at Rexahn Phamaceuticals.com

Report this Post Add Comment | Reply | Permalink
View All 9 Pitches »

Leaderboard

Find the members with the highest scoring picks in RNN.

Score Leader

cecamado1

cecamado1 (99.99) Score: +105.81

The Score Leader is the player with the highest score across all their picks in RNN.

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		Index
Gain 		Score Commentary
detroitigerz 23.98 4/12/2010 Underperform 1Y $3.54 -83.11% +12.10% +95.21 0 Comment
Rihanna 98.43 4/13/2010 Underperform 3M $3.39 -82.36% +12.35% +94.71 0 Comment
Booey66 88.07 4/19/2010 Underperform 5Y $2.35 -74.55% +12.90% +87.45 0 Comment
Vanter1 98.96 4/15/2010 Underperform 3M $2.49 -75.98% +10.98% +86.97 0 Comment
stockjock11 70.86 4/14/2010 Underperform NS $1.97 -69.64% +11.58% +81.22 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. icebit < 20 4/13/2010 Underperform 5Y $1.91 -68.69% +12.23% +80.92 0 Comment
madmac99 82.08 10/18/2010 Underperform 1Y $1.18 -49.32% +14.12% +63.44 1 Comment
marlia79 63.53 4/14/2011 Underperform NS $1.20 -50.17% +2.80% +52.97 0 Comment
hayrettin 69.43 1/18/2012 Outperform 5Y $0.51 +17.72% +2.97% +14.74 0 Comment
grhebert < 20 1/23/2012 Outperform 5Y $0.53 +12.83% +1.68% +11.15 1 Comment
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
TrackBreanMurray 65.65 12/2/2010 Outperform NS $1.17 -48.89% +10.86% -59.75 0 Comment

Featured Broker Partners